HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Unusual response to second-line single-agent gemcitabine in locally advanced primary leiomyosarcoma of the lung: a case report.

Abstract
Primary leiomyosarcomas (LMSs) of the lung are extremely rare malignancies that have been the subject of single or small series of case reports. Today, the gold standard of treatment in patients with locally advanced and metastatic disease includes one of the many possible regimens containing an anthracycline and/or ifosfamide. Few chemotherapy agents are active in the second-line setting. In particular, gemcitabine is considered quite ineffective in the treatment of first- as well as second-line chemotherapy of soft tissue sarcoma and responses to this agent are seldom reported. In this paper, we report a single patient with primary LMS of the lung previously treated with a combination of epirubicin and ifosfamide. The patient responded to second-line chemotherapy with gemcitabine 1250 mg/m2 given as a 30-minute infusion on days 1, 8, and 15 of a 28-day cycle and showed an 8-month response duration and negligible toxicity. Gemcitabine may represent an alternative to the best supportive care in patients affected with soft tissue sarcoma who fail first-line chemotherapy.
AuthorsN Silvestris, D Piscitelli, E Crucitta, M Fiore, M De Lena, V Lorusso
JournalJournal of chemotherapy (Florence, Italy) (J Chemother) Vol. 15 Issue 5 Pg. 507-9 (Oct 2003) ISSN: 1120-009X [Print] England
PMID14603882 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Antimetabolites, Antineoplastic
  • Deoxycytidine
  • Epirubicin
  • Ifosfamide
  • Gemcitabine
Topics
  • Antimetabolites, Antineoplastic (pharmacology, therapeutic use)
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • Deoxycytidine (analogs & derivatives, pharmacology, therapeutic use)
  • Drug Resistance, Neoplasm
  • Epirubicin (administration & dosage, pharmacology)
  • Humans
  • Ifosfamide (administration & dosage, pharmacology)
  • Leiomyosarcoma (drug therapy, pathology)
  • Lung Neoplasms (drug therapy, pathology)
  • Male
  • Middle Aged
  • Gemcitabine

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: